Lee, J L <br/><br/>
RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial.  [electronic resource] 

 -  Annals of oncology : official journal of the European Society for Medical Oncology  Nov 2015 
 - 2300-5 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1569-8041 
<br/><br/><label>Standard No.: </label>10.1093/annonc/mdv357  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Agents--administration & dosage<br/>Carcinoma, Renal Cell--diagnosis<br/>Drug Administration Schedule<br/>Female<br/>Humans<br/>Indoles--administration & dosage<br/>Male<br/>Middle Aged<br/>Pyrroles--administration & dosage<br/>Sunitinib